Perspective Therapeutics CATX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$26.19M-44.1% | -$37.49M+6.7% | -$25.97M-71.7% | -$21.49M-83.6% | -$18.18M-48.0% | ||
| $1.13M+53.8% | $1.01M+42.6% | $775K+15.8% | $733K+28.1% | $732K+106% | ||
| $2.55M+21.7% | $2.31M+12.1% | $2.16M+10.5% | $2.4M+234% | $2.1M+220% | ||
| —— | $0-100% | $0— | $0— | $0— | ||
| $52K+237% | -$173K+20.3% | -$46K— | $147K+118% | -$38K+77.1% | ||
| —— | —— | $0— | $0— | $0+100% | ||
| -$4.21M-146% | —— | $5.54M-64.7% | -$2.84M— | -$1.71M-93.8% | ||
| -$3.61M-40.8% | $778K-75.8% | $1.67M+0.4% | $2.13M+342% | -$2.57M-45.8% | ||
| $327K+236% | -$375K-140% | $0-100% | -$19K— | -$240K-256% | ||
| $51K-43.3% | $44K-20.0% | $58K— | $139K— | $90K— | ||
| -$78K+43.5% | —— | -$14K+79.4% | -$84K+20.8% | -$138K-360% | ||
| $0+100% | —— | —— | —— | -$1.4M-105% | ||
| $392K+430% | —— | $19K— | $212K— | $74K— | ||
| -$31.47M-45.8% | -$24.66M+7.3% | -$16.29M-584% | -$19.95M-124% | -$21.58M-256% | ||
| $6.86M+47.3% | $5.08M-65.3% | $1.99M-93.3% | $1.03M+1.1% | $4.66M-48.7% | ||
| $150.34M+565% | $20.61M-87.5% | $32.13M— | $44.49M— | $22.6M— | ||
| $47.64M+120% | -$119.67M-252% | $48.15M— | $49.82M— | $21.7M— | ||
| —— | $0— | $0— | $0-100% | $0-100% | ||
| -$109.55M-1,869% | $28.54M+121% | $13.99M+147% | $4.26M+229% | -$5.57M+88.2% | ||
| $15K+15.4% | $13K+8.3% | $13K-18.8% | $13K+62.5% | $13K+8.3% | ||
| $290K— | $0-100% | $226K-64.8% | $145K+13.3% | $0-100% | ||
| $164.36M+1,548% | $0-100% | $213K-66.1% | $132K-99.9% | $9.97M-94.0% | ||
| $23.34M+236% | —— | -$2.09M— | -$15.56M-114% | -$17.17M-113% | ||
| —— | $10M— | —— | —— | —— | ||
| $392K+430% | —— | $19K— | $212K— | $74K— | ||
| $0+100% | —— | —— | —— | -$1.4M-105% | ||
| -$3.61M-40.8% | $778K-75.8% | $1.67M+0.4% | $2.13M+342% | -$2.57M-45.8% | ||
| $51K-43.3% | $44K-20.0% | $58K— | $139K— | $90K— | ||
| $327K+236% | -$375K-140% | $0-100% | -$19K— | -$240K-256% | ||
| -$78K+43.5% | —— | -$14K+79.4% | -$84K+20.8% | -$138K-360% | ||
| $0-100% | $51K+6.3% | $39K+62.5% | $36K— | $9K— | ||
| $47.64M+120% | $54.28M— | $48.15M— | $49.82M— | $21.7M— | ||
| $15K+15.4% | $13K+8.3% | $13K-18.8% | $13K+62.5% | $13K+8.3% | ||
| $10.15M— | —— | —— | —— | $0— | ||
| $1.25M— | $205K— | $0-100% | $0-100% | $0-100% | ||
| -$38.33M-46.1% | -$29.73M+27.9% | -$18.28M+30.6% | -$20.98M-112% | -$26.24M-649% | ||
| -$38.33M-46.1% | -$29.73M+27.9% | -$18.28M+30.6% | -$20.98M-112% | -$26.24M-649% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Perspective Therapeutics generate?
- Perspective Therapeutics (CATX) generated -$92.4M in operating cash flow over the trailing twelve months.
- What is Perspective Therapeutics's free cash flow?
- After $15.0M of capital expenditures, Perspective Therapeutics's free cash flow was -$107.3M over the trailing twelve months, down 3.5% year over year.
- Where does Perspective Therapeutics's cash flow data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
